>_ QFI Terminal
Terminal › Stocks › RPRX

Royalty Pharma plc (RPRX) Stock

Healthcare · Medical - Pharmaceuticals · US
$70.01 +0.81%
Last updated Nov 12, 2026 09:30 UTC

RPRX Key Statistics

Market Cap$31.17B
P/E (TTM)49.45
P/S (TTM)11.91
P/B (TTM)3.19
Revenue (TTM)$2.62B
EPS (TTM)$1.42
Dividend Yield—
ROE (TTM)9.95%
Net Margin25.70%
Gross Margin87.34%
52W High$70.27
52W Low$37.31
Analyst ViewBuy
Price Target$66.50
Employees100
Volume3,532,759

About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

CEO: Pablo Legorreta. Company website

RPRX — Frequently Asked Questions

What is the RPRX stock price today?

Royalty Pharma plc (RPRX) trades at $70.01, up 0.81% on the day, as of Nov 12, 2026 09:30 UTC.

What is Royalty Pharma plc's market cap?

Royalty Pharma plc has a market capitalisation of $31.17B, calculated from the live RPRX share price and shares outstanding.

What is the P/E ratio of RPRX?

RPRX trades at a trailing P/E of 49.45, from earnings per share of $1.42 over the last twelve months.

How much revenue does Royalty Pharma plc make?

Royalty Pharma plc generated revenue of $2.62B over the trailing twelve months, which puts the stock at 11.91 times sales.

What is the 52-week range for RPRX?

RPRX has traded between $37.31 and $70.27 over the past 52 weeks, and the last price is 0.4% below that high.

Is Royalty Pharma plc profitable?

Yes. Royalty Pharma plc keeps 25.70% of revenue as net income over the trailing twelve months.

What is the analyst price target for RPRX?

Wall Street analysts rate RPRX Buy, with an average price target of $66.50, 5.0% below the current price.

What sector is Royalty Pharma plc in?

Royalty Pharma plc is classified under the Healthcare sector and the Medical - Pharmaceuticals industry, and is domiciled in US.

Who is the CEO of Royalty Pharma plc?

Pablo Legorreta is the chief executive of Royalty Pharma plc, which employs 100 people.

Where can I track RPRX in real time?

QFI Terminal shows RPRX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.

See RPRX live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open RPRX in Terminal See plans

Medical - Pharmaceuticals stocks

CORT Corcept Therapeutics Incorporated BGMSP Bio Green Med Solution, Inc.

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corp. MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. CNC Centene Corp. ELV Elevance Health Inc. HUM Humana Inc. JNJ Johnson & Johnson LLY Eli Lilly and Company HCA HCA Healthcare, Inc. MRK Merck & Co., Inc. ABBV AbbVie Inc. PFE Pfizer Inc. AZN AstraZeneca PLC NVS Novartis AG SNY Sanofi BMY Bristol-Myers Squibb Company ABT Abbott Laboratories TMO Thermo Fisher Scientific Inc. MOH Molina Healthcare, Inc. AMGN Amgen Inc. MDT Medtronic Plc GSK GSK plc GILD Gilead Sciences, Inc. MDLN Medline Inc. SYK Stryker Corporation DHR Danaher Corporation THC Tenet Healthcare Corporation GEHC GE HealthCare Technologies Inc. BSX Boston Scientific Corporation BDX Becton, Dickinson and Company FMS Fresenius Medical Care AG & Co. KGaA UHS Universal Health Services, Inc. OSCR Oscar Health, Inc. IQV IQVIA Holdings Inc.

ETFs holding RPRX

VLUE iShares MSCI USA Value Factor ETF 0.33% MTUM iShares MSCI USA Momentum Factor ETF 0.28% VYM Vanguard High Dividend Yield ETF 0.10% SCHV Schwab U.S. Large-Cap Value ETF 0.10% DGRO iShares Core Dividend Growth ETF 0.08% IWD iShares Russell 1000 Value ETF 0.07% SCHX Schwab U.S. Large-Cap ETF 0.04% SCHB Schwab U.S. Broad Market ETF 0.04% IWB iShares Russell 1000 ETF 0.04% ACWI iShares MSCI ACWI ETF 0.03% VT Vanguard Total World Stock ETF 0.02%

Largest institutional holders of RPRX

MORGAN STANLEY MS 42,931,597 shares
Capital International Investors 35,273,770 shares
BlackRock, Inc. BLK 27,832,977 shares
FMR LLC 19,348,880 shares
STATE STREET CORP STT 12,338,229 shares
PRICE T ROWE ASSOCIATES INC /MD/ 11,193,657 shares
Swedbank AB 10,260,593 shares
Capital World Investors 9,517,337 shares
BAILLIE GIFFORD & CO 9,151,948 shares
GEODE CAPITAL MANAGEMENT, LLC 8,546,758 shares

RPRX insiders on other boards

JAZZ Jazz Pharmaceuticals plc Love Ted W PODD Insulet Corp. Weatherman Elizabeth H TNET TriNet Group, Inc. Hodgson David C MSCI MSCI Inc. Fernandez Henry A GILD Gilead Sciences, Inc. Love Ted W ZTS Zoetis Inc. Norden Gregory REGN Regeneron Pharmaceuticals, Inc. Bassler Bonnie L MCD McDonald's Corporation Engelbert Catherine M. DNLI Denali Therapeutics Inc. Ho Carole BEAM Beam Therapeutics Inc. Ho Carole